Recursion: FDA OKs Application for Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

 

• First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months

• Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma

https://finance.yahoo.com/news/recursion-announces-fda-clearance-investigational-120000462.html